Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.


NDAQ:RGC - Post by User

User Avatar Image
(0)
•••
  • sungrin1309X
Post by sungrin1309on Dec 21, 2022 4:54am
182 Views
Post# 35183932

Top Performing IPO for 2021 & 2022; $RGC

Top Performing IPO for 2021 & 2022; $RGCTop Performing IPO for 2021 & 2022; $RGC

The year 2021 has seen a huge number of 1,035 companies taking IPO in the US market; where the huge piece of the listings (35%) were in the biotech & healthcare sector. (A possible move by companies to ride on the Covid / Healthcare wave; just thinking out loud).

The company which had the largest gains since IPO does not turn heads when mentioned nor is it a name you seen in ads on television or YouTube. But this company was in the sight of many hedge funds and traders for a while period.

Regencell Bioscience (NASDAQ:[RGC](https://www.benzinga.com/stock/RGC#NASDAQ)). RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.

[A June 2022 article](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.

For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD]) (https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.

Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.

Comparison between the 2 companies can be found in the article link shard at the end of page.

(https://www.benzinga.com/amp/content/28316977)
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities